Ninety One North America Inc. Sells 1,099 Shares of Hologic, Inc. (NASDAQ:HOLX)

Ninety One North America Inc. decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 11.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 8,398 shares of the medical equipment provider’s stock after selling 1,099 shares during the quarter. Ninety One North America Inc.’s holdings in Hologic were worth $605,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in HOLX. FMR LLC increased its holdings in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the period. Nordea Investment Management AB boosted its position in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after acquiring an additional 544,889 shares in the last quarter. Swedbank AB boosted its position in Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after buying an additional 306,562 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after buying an additional 238,222 shares in the last quarter. Finally, Barclays PLC boosted its position in Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after buying an additional 231,578 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

HOLX stock opened at $72.14 on Tuesday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 12 month low of $68.61 and a 12 month high of $84.67. The firm has a market cap of $16.28 billion, a P/E ratio of 21.56, a P/E/G ratio of 2.35 and a beta of 0.98. The company’s 50-day moving average price is $73.19 and its two-hundred day moving average price is $78.03.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period last year, the company posted $0.89 EPS. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have commented on HOLX. JPMorgan Chase & Co. boosted their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. UBS Group upped their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Jefferies Financial Group initiated coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price on the stock. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Monday, January 13th. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and an average target price of $88.92.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.